



Clinical applications of multi-parametric CMR in myocarditis and systemic inflammatory diseases

DOI:

[10.1007/s10554-017-1063-9](https://doi.org/10.1007/s10554-017-1063-9)

Document Version

Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Lagan, J., Schmitt, M., & Miller, C. (2017). Clinical applications of multi-parametric CMR in myocarditis and systemic inflammatory diseases. *The International Journal of Cardiovascular Imaging*. <https://doi.org/10.1007/s10554-017-1063-9>

Published in:

The International Journal of Cardiovascular Imaging

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.



Clinical applications of multi-parametric CMR in myocarditis and systemic inflammatory diseases

Jakub Lagan MB ChB MA^{1,2}, Matthias Schmitt MD PhD¹, Christopher A Miller MB ChB, PhD^{1,2}

1. North West Heart Centre, University Hospital of South Manchester, Manchester, UK.
2. Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK.

Address for correspondence: Christopher A Miller, Institute of Cardiovascular Sciences, Faculty of Medical & Human Sciences, University of Manchester, Manchester M13 9NT, UK.
Email: christopher.miller@manchester.ac.uk

Introduction

The World Health Organisation defines myocarditis as an inflammatory disease of the myocardium diagnosed by established histological, immunological and immunohistochemical criteria.[1] Myocardial involvement in presumed systemic viral infection is the most common aetiology, although it can result from a wide spectrum of infectious pathogens and non-infectious causes including systemic inflammatory conditions and toxins[2,3].

Clinical presentation is often non-specific and heterogeneous, ranging from symptoms of chest pain, dyspnoea, fatigue or palpitations to brady- and tachy-arrhythmias, cardiogenic shock and sudden death[2]. Peripheral markers of inflammation (e.g. c-reactive protein) and myocardial injury (e.g. troponin) lack sensitivity and specificity, and viral serology is unhelpful.[4-6] Invasive endomyocardial biopsy (EMB) is recommended in specific scenarios, such as “New-onset heart failure of 2 weeks duration associated with a normal-sized or dilated left ventricle and hemodynamic compromise (IB)” and “New-onset heart failure of 2 weeks to 3 months duration associated with a dilated left ventricle and new ventricular arrhythmias, second- or third-degree heart block, or failure to respond to usual care within 1 to 2 weeks (1B)”,[7] however, it is associated with a risk of complications (1-2%) and due to sampling error, transiency of myocardial injury and variation in histology interpretation, it also lacks accuracy.[8,2,9-12] In most centres it is rarely performed. As a result of these factors, the diagnosis of myocarditis is challenging, and has traditionally been made after other cardiac diseases have been excluded.[2]

Over the past decade, cardiac magnetic resonance (CMR) has changed this paradigm. The unique ability of multiparametric CMR to characterise myocardial tissue, and thus potentially detect the myocardial oedema, increased blood flow and capillary leakage, necrosis and subsequent fibrosis that occurs in myocarditis, coupled with the ability of CMR to detect subtle regional or global contractile dysfunction, means that CMR is now often able to

provide a positive diagnosis of myocarditis. Indeed, CMR has provided pathophysiological insight into the nature of the myocardial injury in myocarditis.

This review will describe the diagnostic utility of CMR parameters across a range of myocarditic aetiologies. In this context, it is important to recognise that the evaluation of CMR, or indeed any diagnostic test, in myocarditis is limited by the lack of a good reference standard. Histological validation is challenging and imperfect, as described. As a result, many studies use a clinical diagnosis of myocarditis as the reference, however this is inherently limited. In addition, heterogeneous study designs and patient populations (e.g. acute versus chronic myocardial inflammation, definition of control groups), and the nature of CMR (differing magnetic field strengths, imaging sequences, measured parameters) makes comparisons between studies difficult.

Idiopathic (presumed viral) Myocarditis

In North America and Europe, myocardial involvement in presumed systemic viral infection remains the most common aetiology of myocarditis[2,13-18].

T2 weighted imaging

T2 relaxation is directly proportional to tissue water content, and T2 weighted (T2w) imaging has been proposed to detect myocardial oedema.[19,20,3]

Table 1 summarises studies that have evaluated the diagnostic performance of T2w imaging, including the sequences employed, the populations studied and the reference standards.[21-35]. Most studies analyse T2w images using an oedema ratio (ER), defined as the ratio of myocardial to skeletal muscle signal intensity (SI), with values above a set value considered pathological. However, the threshold varies across studies (1.8 - 2.2), is usually determined retrospectively and the technique is hampered by potential coexistence of myositis and a lack of skeletal muscle in the field of view.[21,35] A minority of studies have

used qualitative assessment, although a lack of 'healthy' myocardium for comparison in the context of global myocarditis is a limitation.[35]

The pooled weighted sensitivity, specificity and diagnostic accuracy of T2w for diagnosing acute myocarditis are 63%, 76% and 68% respectively.

In the largest study (104 patients), in which a clinical diagnosis of myocarditis was used as the reference standard, Radunski et al reported a modest diagnostic accuracy (70%).[31] Median interval between symptom onset and scan was 2 weeks, however the interquartile range was up to 7 weeks, by which time patients may have been in the convalescent stage. Indeed, the effect of delayed scan timing on T2w imaging sensitivity was investigated by Monney et al[36] and Hinojar et al[34], who found a higher prevalence of abnormal signal on T2w images when scanning within 2 weeks of symptom onset (81% and 56% respectively) compared to scanning performed later (11% at 39 days[36] and 12% at 6 months[34]). Other studies comparing acute and convalescent imaging have also shown that high T2 signal is a transient feature of inflammatory response.[36-40] In addition, abnormalities detectable on T2w imaging appear to vary according to clinical presentation, with a higher prevalence in the context of infarction-like symptoms (81% sensitivity) and much lower in the setting of heart failure or arrhythmias (sensitivity 28% and 27% respectively).[41]

Early Gadolinium enhancement

Early gadolinium enhancement exploits the phenomenon of regional vasodilatation, increased blood flow and capillary leakage present in an inflammatory process which results in increased contrast retention in the early washout period[3].

Table 2 summarises studies that have evaluated the diagnostic performance of EGE imaging.[42,3,21-27,29,32,31,33,35] Analysis of EGE images is performed using Myocardial Signal Enhancement, defined as myocardial SI post-contrast minus myocardial SI pre-

contrast divided by myocardial SI pre-contrast, with values above 45% - 56% considered pathological[21,29,31], or more commonly, the global relative enhancement (gRE),[42] which is calculated as myocardial signal enhancement divided by skeletal muscle signal enhancement. Most studies use a gRE value of 4.0 as the threshold between healthy and abnormal myocardium[22,23,25,24,26,27,32]. Such analyses have similar disadvantages to the ER.

The pooled weighted sensitivity, specificity and diagnostic accuracy of EGE for diagnosing acute myocarditis are 66%, 70% and 67% respectively, with a wide range of diagnostic performances reported for both myocardial signal enhancement and gRE analysis techniques. Interestingly, Bohnen et al, found no statistical difference in gRE between heart failure patients with histologically confirmed inflammation and those without.[43]

Friedrich et al[42,44] found the pattern of signal enhancement was localised within first week but subsequently became more diffuse. By day 14, gRE values stopped being significantly higher in the myocarditis group compared to the control group. Studies comparing EGE in acute and convalescent phases show a significant drop in gRE, from 4.1 – 8.5 during acute presentation to 2.4 – 4.4 at follow up (performed 3 – 28 months later). [38,39,37,40]

Late gadolinium enhancement

LGE was originally thought to demonstrate irreversible myocardial injury only, however several studies have demonstrated a temporal change in the extent of LGE in myocarditis, with LGE volume seen to decrease significantly over time (follow up scans performed between 1 and 18 months).[3,36,40,45,37,38] Histological correlation has shown LGE is associated with active inflammation, with the extent of LGE corresponding to the severity of the inflammatory histopathological findings.[46,45] It is likely that LGE in acute myocarditis represents both reversible and irreversible myocardial injury, but in the chronic phase represents residual focal fibrosis. See Figure 1A for a representative example.

Table 3 summarises studies that have evaluated the diagnostic performance of late gadolinium enhancement (LGE) imaging. [22,45,23,47,24-27,29,30,32,31,33-35]. The pooled weighted sensitivity, specificity and diagnostic accuracy of LGE for diagnosing acute myocarditis are 65%, 95% and 75% respectively. The prevalence of LGE varies considerably across studies (27% - 95%), likely reflecting the heterogeneity of the populations studied and the timing of CMR.[48-50,40,36,51,22,45,23,47,24-27,29,30,32,31,33,35,34]

While a number of studies have shown that LGE can involve any region of the LV (or the right ventricle), Mahrholdt et al,[46] in seminal work, showed LGE is most commonly located in the lateral LV, typically originating from the epicardial quartile of the LV wall. Transmural lateral wall LGE, possibly reflecting very florid disease, is reported in a minority[22,49,52,45,50,47,40,36,51,27,30,33,26,53,23]. The distribution of LGE may be associated with the infecting pathogen, with parvovirus B19 found to be association with sub-epicardial lateral wall LGE, whereas human herpes virus 6 is associated with mid wall septal LGE[45].

LGE imaging requires the presence of 'normal' myocardium as a reference, thus may not be sensitive to diffuse disease.[54]

Lake Louise Criteria

In an effort to increase the diagnostic performance of CMR, the three tissue characterisation techniques discussed above (T2w imaging, EGE and LGE) were combined to form the Lake Louise Criteria (LLC). In the setting of clinically suspected myocarditis, abnormal findings on 2 of the 3 techniques were determined to be consistent with myocardial inflammation[3].

Table 4 summarises studies that have evaluated the diagnostic performance of the LLC. [22,23,25-27,32,31,33,35] The pooled weighted sensitivity, specificity and diagnostic accuracy of the LLC for diagnosing acute myocarditis are 80%, 87% and 83% respectively, and as such the LLC demonstrate a better overall diagnostic performance than any of the individual CMR parameters. Similar to T2w imaging, LLC appears to have better diagnostic performance in “infarct-like” presentation (sensitivity of 80%) compared to heart failure or arrhythmias (sensitivity 57% and 40% respectively).[41]

Parametric mapping

In recent years, parametric mapping, which allows direct quantification of myocardial tissue magnetic parameters (primarily T1 and T2) has been increasingly applied in myocarditis. (Similar to T2, T1 relaxation times are sensitive to changes in myocardial water content and have been proposed to detect myocardial oedema). As well as being associated with potentially less observer variability, less artefact and allowing global myocardial assessment, native T1 and T2 mapping offer the significant advantage of not requiring contrast agent administration. See Figures 1B and 1C for representative examples.

Table 5 summarises the studies that have evaluated the diagnostic performance of T2 and T1 mapping. The pooled weighted sensitivity, specificity and diagnostic accuracy of T2 mapping for diagnosing acute myocarditis are 70%, 91% and 79% respectively. [51,31,43,55,35]. The pooled weighted sensitivity, specificity and diagnostic accuracy of T1 mapping are 82%, 91% and 86%.[30,32,31,34,35] Thus the diagnostic performance of T2 mapping is comparable to that of the LLC, while the performance of T1 mapping may be superior.

Luetkens et al compared the diagnostic performance of CMR parameters in two studies, albeit in relatively small populations (24 and 34 patients with myocarditis respectively), and demonstrated similar findings. In the first study, which did not include T2 mapping[32], native

T1 mapping was associated with the highest diagnostic performance (area under the curve, AUC 0.94), followed by LGE (AUC 0.9), LLC (AUC 0.86), ER (AUC 0.79) and gRE (AUC 0.63). In the second study, which included T2 mapping,[35], the performance of native T1 mapping (AUC 0.92 - 0.95) and T2 mapping (AUC 0.92) was very similar. Combining T1 mapping with LGE (diagnostic accuracy 91 - 96%)[30,32,34,35] or T2 mapping and LGE (diagnostic accuracy 96%) [35] may improve diagnostic performance further.

Nevertheless, there are a number of areas which require further investigation. Only one study has compared T1 and T2 mapping with histological findings in myocarditis. Relaxation time thresholds for diagnosing myocarditis have generally been determined retrospectively. T1 relaxation time diagnostic thresholds vary considerably between studies (852 – 1074 ms at 1.5T). T2 relaxation time diagnostic thresholds are generally much more consistent (approximately 60ms), however they overlap considerably with published normal ranges (up to 65ms).[56-62,51,63-66] A prospective, multicentre, multivendor trial with predetermined diagnostic thresholds is required to determine the clinical diagnostic utility of mapping with quantitative analysis before this technique can enter clinical practice.

Other noteworthy findings include those of Hinojar et al, who showed elevated T1 values (compared to healthy controls) persisted for up to 4-8 months post initial presentation.[34] Bohnen et al found no difference in T1 values in patients with heart failure and histologically confirmed inflammation compared to patients with heart failure and no evidence of inflammation on histology.[43] This may reflect the fact that native T1 is determined by a number of factors other than inflammation (e.g. fibrosis).

Only three studies have examined the diagnostic utility of ECV in myocarditis, with varying results (Table 5).[31,32,35]

Acute cardiac allograft rejection

Acute cardiac allograft rejection (ACAR) is a leading cause of death in the first year post heart transplant, however clinical features are unreliable. Routine screening is therefore performed in order to detect ACAR and hence augment immunosuppressive therapy, at an earlier stage, with the aim of preventing progression to more severe disease.[67,68] Histological analysis of myocardial tissue obtained at EMB remains the gold standard for ACAR surveillance however it is associated with a number of limitations. CMR is a potentially attractive screening modality.

In one of the largest human studies, which included 68 patients undergoing 123 CMR scans, T2 relaxation time was significantly higher in grade 2 ACAR (57 ± 5 ms) compared with grade 0 or 1 (50 ± 5 ms and 51 ± 8 ms, respectively); and in grade 3 (65 ± 8 ms) compared with grade 2.[69] A T2 relaxation time of ≥ 56 ms, determined retrospectively, had a high NPV (97%) for detecting significant ACAR (\geq grade 2). More recently in a study of approximately 50 patients undergoing 68 CMR scans, Usman et al found myocardial T2 was significantly higher in the ACAR group (including 4 cases of $>$ grade 2R ACAR, 2 cases of antibody-mediated rejection and 2 cases where ACAR treatment was started on the basis of high clinical suspicion alone) compared to the non-ACAR group.[70] A T2 of 56.4 ms yielded a sensitivity and specificity of 86.5% and 94.6% respectively. However, both studies specifically selected patients who were known to have/suspected of having ACAR. Furthermore, patients were scanned at a substantial time post-transplant (Marie et al up to 6 years, Usman et al up to 2 years), thus missing the window in which early detection of ACAR is thought to be most useful, indeed the benefit of routine screening later than one year post-transplant is subject to debate.

In a study of 22 patients undergoing 88 CMR scans over the first 5 months post-transplant, Miller et al found myocardial T1 and T2 were not significantly higher in grade 2R ACAR compared to grades 0R-1R.[71] However the study did demonstrate significant improvements in markers of LV structure and contractility, native T1, T2 and ECV and

microvascular function over the period studied, providing insight into the myocardial injury associated with transplantation, and its recovery.

It may be that CMR parameters become more useful for detecting ACAR as time from transplantation increases and the transplant-related myocardial injury subsides. The paradox however is that while non-invasive approaches to ACAR surveillance may become more discriminatory as time from transplantation increases, the benefit of the early detection of ACAR diminishes.[71]

Sarcoidosis

Sarcoidosis is a multi-organ systemic inflammatory disorder characterized by the formation of non-caseating granulomas[72]. Autopsy studies suggest cardiac sarcoidosis is a major cause for sarcoid-related mortality, however pre-mortem diagnosis of cardiac sarcoid is challenging[72,73]. Endomyocardial biopsy and clinical diagnostic criteria[74] are limited[75]

Smedema et al[76] found LGE in all patients (n=12) meeting clinical criteria for cardiac sarcoid, and in a further 17% who did not meet the criteria. Patel et al[77] showed CMR identified twice as many patients (n=21) with evidence of myocardial involvement as clinical evaluation, which included 12-lead ECG and at least one non-CMR cardiac investigation (echocardiography, radionuclide scintigraphy or cardiac catheterisation).

Regional and mural LGE distribution in cardiac sarcoid is markedly heterogeneous. LGE has been demonstrated in all LV and RV regions, albeit with some predilection to basal septal regions.[76-80] Subendocardial, mid wall, epicardial and transmural patterns have been described. [76-80] Using T2 mapping, Crouser et al[81] found significantly higher myocardial T2 values amongst 50 consecutive patients investigated for cardiac sarcoid compared to healthy controls. T2 cut off of 59 ms achieved sensitivity of 54% and specificity of 100%.

¹⁸F-fluoro-2-deoxyglucose positron emission tomography (¹⁸F-FDG PET; a marker of active inflammation) studies have provided insight into the CMR findings.[82,83] T2w signal and LGE have been demonstrated to correspond to regions taking up ¹⁸F-FDG, with reduced uptake following corticosteroids, indicating active inflammation. However, LGE is also found in regions without ¹⁸F-FDG uptake, indicating fibrotic lesions. Thus T2w signal may reflect active inflammation, whereas LGE may reflect either active inflammation or fibrosis.

The presence of LGE is associated with a higher rate of sudden cardiac death (SCD) and ventricular tachyarrhythmia, although this requires further assessment in larger studies.[77-79,84]

Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a multisystem inflammatory disorder.[85]

Cardiovascular involvement represents a significant cause of morbidity and mortality.[86]

SLE associated myocarditis was shown to shorten the survival and is more common amongst patients with higher disease activity.[87] There is also a discrepancy between the number of myocarditis cases detected on autopsy and clinical diagnoses, suggesting common subclinical cardiac involvement.[88,89] There is considerable interest in the accurate detection of myocardial involvement in SLE, and other rheumatological conditions, as it may potentially guide therapy aimed at reducing adverse cardiovascular outcomes.

A small study by Singh et al[90] showed that T2 relaxation times were higher in six patients with active SLE compared to five with lower disease activity and five healthy controls (T2 values of 82 ms, 64 ms and 65 ms respectively). Similarly, Abdel-Aty et al[88] showed that both ER and gRE were significantly higher in patients with active disease, both correlated to disease activity and ER significantly decreased with clinical improvement.

Mavrogeni et al[89] compared a group of twenty five patients with active SLE and suspected cardiac involvement with fifty patients suspected of having viral myocarditis showing no statistical difference in ER and EGE, potentially suggesting similar myocardial pathological processes in both conditions.

Puntmann et al[91] showed that T1 and ECV values were significantly higher among thirty three SLE patients in clinical remission compared to twenty one healthy controls (T1 1152 ± 46 ms versus 1056 ± 27 ms, $p < 0.001$; ECV $30\pm 6\%$ versus $26\pm 5\%$, $p = 0.007$). A challenge for the CMR community is to decipher whether such findings represent active inflammation or chronic fibrosis, or indeed both. The authors did not perform T2 mapping, however, ER did not differ between groups, potentially suggesting the T1 and ECV findings may represent fibrosis. Conversely, Zhang et al[92] demonstrated higher T2 values in twenty four SLE patients with low disease activity compared to twelve healthy controls (58.2 ± 5.6 ms versus 52.8 ± 4.4 ms), which the authors suggested may represent ongoing myocardial inflammation.

LGE may be less prevalent in SLE. Zhang et al[92] observed no late enhancement amongst twenty four SLE patients while Mavrogeni et al[89] found significantly less LGE amongst patients with active SLE compared to viral myocarditis (LGE volume $3.5\pm 5.5\%$ versus $8\pm 4.4\%$, $p < 0.001$), possibly reflecting a more diffuse nature of myocardial involvement.

Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease[93]. Cardiovascular involvement is common, manifesting as coronary artery disease, myocardial inflammation and fibrosis, and is responsible for 40 - 80% of premature deaths. [94-97].

Kobayashi et al[98] examined eighteen RA patients without a previous history of cardiovascular conditions, finding LGE in almost 40% of patients, with a mostly non-

ischaemic distribution. The presence of LGE was correlated to higher disease activity scores (DAS28 4.77 versus 3.44, $p = 0.011$).

Mavrogeni et al[99] used T2w imaging, EGE and LGE to compare two groups of RA patients in remission: twenty with and twenty without recent onset cardiac symptoms. 10% of patients with symptoms had evidence of myocardial infarction with a typical ischaemic LGE pattern and 65% displayed evidence of myocarditis as defined by LLC. Over three quarters of those diagnosed with myocarditis experienced an RA relapse within 6 weeks, possibly suggesting more active disease.

Ntusi et al[100] found LGE to be present in almost half of twenty eight examined RA patients with a mostly non-ischaemic, mid wall pattern. In addition, 5% of patients were diagnosed with silent myocardial infarction based on the presence of subendocardial LGE and confirmed by coronary angiography. There was no difference in global ER between RA patients and controls, however, RA patients had more areas of elevated ER (ER > 1.9, median 10% versus 0% amongst controls) suggesting the presence of focal myocardial oedema. Finally, global T1 values and ECV were significantly higher in the RA group (T1 973 ± 27 ms versus 961 ± 18 ms, $p = 0.03$; ECV $30.3 \pm 3.4\%$ versus $27.9 \pm 2\%$, $p < 0.001$). Although, in keeping with the findings in SLE, it is not clear to what extent these findings represent active inflammation or fibrosis and the magnitude of the difference in global T1, whilst statistically significant, were small.

It is clear from these CMR studies that subclinical cardiac involvement is common. CMR parameters have the potential to risk stratify and guide therapy in RA, although further work is required to define the nature of the CMR findings in RA and their accuracy and reproducibility in this population.

Systemic sclerosis

Systemic Sclerosis (SSC) is an autoimmune connective tissue disorder characterised by multi-organ fibrosis[101]. Cardiac involvement in SSC is estimated at 15-35%[101] and includes myocardial fibrosis, myocarditis, dilated cardiomyopathy, premature coronary artery disease, conduction abnormalities, valvular and pericardial disease[102]. Myocardial pathologies are often subclinical with higher prevalence on autopsy studies[103]. Overt cardiac disease is associated with poor prognosis, with a reported 70% mortality at 5 years[104].

A number of studies have evaluated LGE in SSC patients, demonstrating a prevalence of LGE of between 4% and 66%[105-114]. LGE prevalence and distribution does not seem to differ between limited and diffuse cutaneous forms of SSC[105,106,108,113]. Both non-ischaemic and ischaemic patterns of LGE are described [105-112] It is not clear whether the non-ischaemic LGE represents inflammation or fibrosis. Microvascular dysfunction is a prominent feature of SSC and diffuse myocardial ischaemia evident on perfusion imaging may be part of the pathophysiological process[113,107].

In a study by Hachulla et al[106] fifty two SSC patients without prior cardiac disease were assessed by multiparametric CMR. Qualitative T2w signal was increased in 12% of participants. Ntusi et al[110] study found nineteen SCC patients to have a significantly greater extent of high gRE values compared to twenty healthy controls[110]. There was no difference between limited and diffuse cutaneous SSC[106,110].

T1 mapping and ECV values were also shown to be higher in SSC patients without past cardiovascular involvement. In previously mentioned study by Ntusi et al[110], SSC participants had mean T1 values of 1007 ± 29 ms and ECV of 35.4 ± 4.8 % compared to T1 of 958 ± 20 ms ($p < 0.001$) and ECV of 27.6 ± 2.5 % ($p < 0.001$) amongst controls. Two further studies confirmed higher ECV in SSC patients compared to healthy controls: Barison et al[109] (30 SSC patients, ECV $30 \pm 4\%$ versus $28 \pm 4\%$, $p = 0.03$) and Thuny et al[115] (33

SSC patients, median ECV 30%, range 28 – 31.9% versus 26.8%, range 25.4% - 29.1%, p = 0.001).

Conclusions

By providing a 'positive' diagnostic test, CMR has changed the management of suspected viral myocarditis and has provided new insight into myocardial involvement in systemic inflammatory conditions. Thus CMR has opened a window for potential therapeutic targets. Parametric mapping appears to offer advantages over more conventional CMR techniques. However, multicentre, multivendor clinical trials are required to fully establish the clinical utility of CMR in myocarditis, and, in particular, quantitative mapping analysis.

Compliance with ethical standards:

No extra funding was received by any of the authors. All three authors are employed at the University Hospital of South Manchester. Dr Lagan holds the position of a cardiology research fellow. Dr Schmitt holds the position of a cardiology consultant. Dr Miller holds the position of a cardiology consultant and a clinical lecturer.

Conflict of Interest:

All three authors declare no conflicts of interest.

Ethical approval:

This article does not contain any studies with human participants or animals performed by any of the authors.

Acknowledgments

Dr Miller is supported by a National Institute for Health Research Clinician Scientist Award ([CS-2015-15-003]CS-2015-15-003).

References:

1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfás I, Martin I (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. *Circulation* 93:841-842
2. Caforio A, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix S, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto Y, Ristic A, Schultheiss H-P, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: . *Eu Heart J* 34:2636–2648
3. Friedrich M, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper L, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy J-P, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P (2009) Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper. *J Am Coll Cardiol*
4. Mahfoud F, Gärtner B, Kindermann M, Ukena C, Gadomski K, Klingel K, Kandolf R, Böhm M, Kindermann I (2011) Virus serology in patients with suspected myocarditis: utility or futility? *Eur Heart J* 32:897 - 903
5. Laurer B, Niederau C, Ku U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP (1997) Cardiac Troponin T in Patients With Clinically Suspected Myocarditis. *J Am Coll Cardiol* 30:1354 - 1359
6. Smith SC, Ladenson JH, Mason JW, Jaffe AS (1997) Elevations of Cardiac Troponin I Associated With Myocarditis: Experimental and Clinical Correlates. *Circulation* 95:163-168
7. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R (2007) The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. *Circulation* 116:2216 - 2233
8. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, Klingel K, Kandolf R, Sechtem U, Cooper LT, Böhm M (2012) Update on myocarditis. *J Am Coll Cardiol* 59:779–792
9. Leonea O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, Bruneval P, Burkeg M, Butanyh J, Calabrese F, d'Amati G, Edwards WD, Fallon JT, Fishbein MC, Gallagher PJ, Halushka MK, McManuso B, Pucci A, Rodriguez R, Saffitz JE, Sheppard MN, Steenbergen C, Stone JR, Tan C, Thiene G, vanderWal AC, Winters GL (2012) 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. *Cardiovas Pathol* 21:245–274
10. Kriehoff C, Barten MJ, Hildebrand L, Grothoff M, Lehmkuhl L, Lücke C, Andres C, Nitzsche S (2014) Assessment of sub-clinical acute cellular rejection after heart transplantation: comparison of cardiac magnetic resonance imaging and endomyocardial biopsy. *Eur Radiol* 24:2360-2371
11. Yilmaz A, Klingel K, Kandolf R, Sechtem U (2009) Imaging in inflammatory heart disease: from the past to current clinical practice. *Hellenic J Cardiol* 50:449-460
12. Baughman KL (2006) Diagnosis of myocarditis: death of Dallas criteria. *Circulation* 113:593-595
13. Bock CT, Klingel K, Kandolf R (2010) Human Parvovirus B19–Associated Myocarditis. *N Engl J Med* 362:1248-1249
14. Baboonian C, Treasure T (1997) Meta-analysis of the association of enteroviruses with human heart disease. *Heart* 78:539–543
15. Cambridge G, MacArthur CGC, Waterson AP, Goodwin JF, Oakley SM (1979) Antibodies to Coxsackie B viruses in congestive cardiomyopathy. *Brit Heart J* 41:692-696
16. Martin AB, Webber S, Fricker FJ, Jaffe R, Demmler G, Kearney D, Zhang Y-H, Bodurtha J, Gelb B, Ni J, Bricker T, Towbin JA (1994) Acute Myocarditis Rapid Diagnosis by PCR in Children. *Circulation* 90:330-339
17. Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss H-P (2005) High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With "Idiopathic" Left Ventricular Dysfunction. *Circulation* 111:887-893

18. Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss H-P, McCarthy R, Hare J, Bricker JT, Bowles KR, Towbin JA (2003) Detection of Viruses in Myocardial Tissues by Polymerase Chain Reaction: Evidence of Adenovirus as a Common Cause of Myocarditis in Children and Adults. *J Am Coll Cardiol* 42:466-472
19. Higgins CB, Herfkens R, Lipton MJ, Sievers R, Sheldon P, Kaufman L, Crooks LE (1983) Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. *Am J Cardiol* 52:184-188
20. Ridgway JP (2010) Cardiovascular magnetic resonance physics for clinicians: part I. *J Cardiovasc Magn Reson* 12:71
21. Laissy JP, Messin B, Varenne O, Lung B, Karila-Cohen D, Schouman-Claeys E, Steg PG (2002) MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. *Chest* 122:1638–1648
22. Abdel-Aty H, Boye P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, Bock P, Dietz R, Friedrich MG, Schulz-Menger J (2005) Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. *J Am Coll Cardiol* 45:1815–1822
23. Gutberlet M, Spors B, Thomas T, Bertram H, Denecke T, Felix R, Noutsias M, Schultheiss H-P, Kuhl U (2008) Suspected Chronic Myocarditis at Cardiac MR: Diagnostic Accuracy and Association with Immunohistologically Detected Inflammation and Viral Persistence. *Radiology* 246:401-409
24. Röttgen R, Christiani R, Freyhardt P, Gutberlet M, Schultheiss HP, Hamm B, Kuhl U (2011) Magnetic resonance imaging findings in acute myocarditis and correlation with immunohistological parameters. *Eur Radiol* 21:1259–1266
25. Voigt A, Elgeti T, Durmus T, Idiz ME, Butler C, Beling M, Schilling R, Klingel K, Kandolf R (2011) Cardiac magnetic resonance imaging in dilated cardiomyopathy in adults—towards identification of myocardial inflammation. *Eur Radiol* 21:925–935
26. Lurz P, Eitel I, Adam J, Steiner J, Grothoff M, Desch S, Fuernau G, deWaha S, Sareban M, Luecke C, Klingel K, Kandolf R, Schuler G, Gutberlet M, Thiele H (2012) Diagnostic Performance of CMR Imaging Compared With EMB in Patients With Suspected Myocarditis. *JACC Cardiovasc Imaging* 5:513-524
27. Chu GCW, Flewitt JA, Mikami Y, Vermes E, Friedrich MG (2013) Assessment of acute myocarditis by cardiovascular MR: diagnostic performance of shortened protocols. *Int J Cardiovasc Imaging* 29:1077–1083
28. Ferreira VM, Piechnik SK, Dall'Armellina E, Karamitsos TD, Francis JM, Ntusi N, Holloway C, Choudhury RP, Kardos A, Robson MD, Friedrich MG, Neubauer S (2013) T1 Mapping for the Diagnosis of Acute Myocarditis Using CMR Comparison to T2-Weighted and Late Gadolinium Enhanced Imaging. *JACC Cardiovasc Imaging* 6:1048-1058
29. Šramko M, Kubánek M, Tintěra J, Kautznerová D, Weichet J, Malušková J, Franeková J, Kautzner J (2013) Utility of Combination of Cardiac Magnetic Resonance Imaging and High-Sensitivity Cardiac Troponin T Assay in Diagnosis of Inflammatory Cardiomyopathy. *Am J Cardiol* 111:258-264
30. Ferreira VM, Piechnik SK, Dall'Armellina E, Karamitsos TD, Francis JM, Ntusi N, Holloway C, Choudhury RP, Kardos A, Robson MD, Friedrich MG, Neubauer S (2014) Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents. *J Cardiovasc Magn Reson* 16:36
31. Radunski UK, Lund GK, Stehning C, Schnackenburg B, Bohnen S, Adam G, Blankenberg S, Muellerleile K (2014) CMR in Patients With Severe Myocarditis Diagnostic Value of Quantitative Tissue Markers including Extracellular Volume Imaging. *JACC Cardiovasc Imaging* 7:557-575
32. Luetkens JA, Doerner J, Thomas DK, Dabir D, Gieseke J, Sprinkart AM, Fimmers R (2014) Acute Myocarditis: Multiparametric Cardiac MR Imaging. *Radiology* 273:383-392
33. Schwab J, Rogg HJ, Pauschinger M, Fessele K, Bareiter T, Bär I, Loose R (2015) Functional and Morphological Parameters with Tissue Characterization of Cardiovascular Magnetic Imaging in Clinically Verified "Infarct-like Myocarditis". *Rofo* 2015 Nov 27

34. Hinojar R, Foote L, Ucar EA, Jackson T, Jabbour A, Yu CY, McCrohon J, Higgins DM, Carr-White G (2015) Native T1 in Discrimination of Acute and Convalescent Stages in Patients With Clinical Diagnosis of Myocarditis A Proposed Diagnostic Algorithm Using CMR. *8:37-46*
35. Luetkens JA, Homsy R, Sprinkart AM, Doerner J, Dabir D, Kuetting DL, Block W, Andrie R (2016) Incremental value of quantitative CMR including parametric mapping for the diagnosis of acute myocarditis. *Eur Heart J Cardiovasc Imaging 17:154-161*
36. Monney PA, Sekhri N, Burchell T, Knight C, Davies C, Deaner A, Sheaf M, Baithun S, Petersen S, Wragg A, Jain A, Westwood M, Mills P, Mathur A, Mohiddin SA (2011) Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis. *Heart 97:1312-1318*
37. Mavrogeni S, Spargias C, Bratis C, Kolovou G, Markussis V, Papadopoulou E, Constadoulakis P, Papadimitropoulos M, Douskou M, Pavlides G, Cokkinos D (2011) Myocarditis as a precipitating factor for HF: evaluation and 1-year follow-up using CMR and endomyocardial biopsy. *Eur J Heart Fail 13:830-837*
38. Mavrogeni S, Bratis K, Georgakopoulos D, Karanasios E, Kolovou G, Pavlides G, Papadopoulos G (2012) Evaluation of myocarditis in a pediatric population using CMR and endomyocardial biopsy. *Int J Cardiol 160:192-195*
39. Stensaeth KH, Hoffmann P, Fossum E, Mangschau A, Sandvik L, Klow NE (2012) Cardiac magnetic resonance visualizes acute and chronic myocardial injuries in myocarditis. *Int J Cardiovasc Imaging 2:327-335*
40. Zagrosek A, Abdel-Aty H, Boyé P, Wassmuth R, Messroghli D, Utz W, Rudolph A, Bohl S, Dietz R, Schulz-Menger J (2009) Cardiac magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis. *JACC Cardiovasc Imaging 2:131-138*
41. Francone M, Chimenti C, Galea N, Scopelliti F, Verardo R, Galea R, Carbone I, Catalano C (2014) CMR Sensitivity Varies With Clinical Presentation and Extent of Cell Necrosis in Biopsy-Proven Acute Myocarditis. *JACC Cardiovasc Imaging 7:254-263*
42. Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R (1998) Contrast Media-Enhanced Magnetic Resonance Imaging Visualizes Myocardial Changes in the Course of Viral Myocarditis. *Circulation 97:1802-1809*
43. Bohnen S, Radunski UK, Lund GK, Kandolf R, Stehning C, Schnackenburg B, Adam G (2015) Performance of T1 and T2 Mapping Cardiovascular Magnetic Resonance to Detect Active Myocarditis in Patients With Recent-Onset Heart Failure. *Circ Cardiovasc Imaging 8:e003073*
44. Wagner A, Schulz-Menger J, Dietz R, Friedrich MG (2003) Long-term follow-up of patients with acute myocarditis by magnetic resonance imaging. *Magma 16:17-20*
45. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock C-T, Klingel K, Kandolf RR, Sechtem U (2006) Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis. *Circulation 114:1581-1590*
46. Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, Fritz P, Klingel K, Kandolf R, Sechtem U (2004) Cardiovascular Magnetic Resonance Assessment of Human Myocarditis: A Comparison to Histology and Molecular Pathology. *Circulation 109:1250-1258*
47. Yilmaz A, Mahrholdt H, Athanasiadis A, Vogelsberg H, Meinhardt G, Voehringer M, Kispert EM, Deluigi C, Baccouche H, Spodarev E, Klingel K, Kandolf R, Sechtem U (2008) Coronary vasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis. *Heart 94:1456-1463*
48. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, Hill S, Mahrholdt H, Voehringer M, Schieber M, Klingel K, Kandolf R, Bohm M, Sechtem U (2010) Comparative Evaluation of Left and Right Ventricular Endomyocardial Biopsy Differences in Complication Rate and Diagnostic Performance. *Circulation 122:900-909*
49. Cobelli FD, Pieroni M, Esposito A, Chimenti C, Belloni E, Mellone R, Canu T, Perseghin G, Gaudio C, Maseri A, Frustaci A, Maschio AD (2006) Delayed Gadolinium-Enhanced Cardiac Magnetic Resonance in Patients With Chronic Myocarditis Presenting With Heart Failure or Recurrent Arrhythmias *J Am Coll Cardiol 47:1649-1654*

50. Yelgec NS, Dymarkowski S, Ganame J, Bogaert J (2007) Value of MRI in patients with a clinical suspicion of acute myocarditis. *Eur Radiol* 17:2211–2217
51. Thavendiranathan P, Walls M, Gir S, Verhaert D, Rajagopalan S, Moore S, Simonetti OP, Raman SV (2012) Improved Detection of Myocardial Involvement in Acute Inflammatory Cardiomyopathies Using T2 Mapping *Circ Cardiovasc Imaging* 5:102-110
52. Laissy JP, Hyafil F, Feldman LJ, Juliard J-M, Schouman-Claeys E, Steg PG, Faraggi M (2005) Differentiating Acute Myocardial Infarction from Myocarditis: Diagnostic Value of Early- and Delayed-Perfusion Cardiac MR Imaging. *Radiology* 237:75-82
53. Banka P, Robinson JD, Uppu SC, Harris MA, Hasbani K, Lai WW, Richmond ME, Fratz S, Jain S (2015) Cardiovascular magnetic resonance techniques and findings in children with myocarditis: a multicenter retrospective study. *J Cardiovasc Magn Reson* 17:96
54. Kim RJ, Shah DJ, Judd RM (2003) How We Perform Delayed Enhancement Imaging. *J Cardiovasc Magn Reson* 5:505-514
55. Baeßler B, Schaarschmidt F, Dick A, Stehning C, Schnackenburg B, Michels G, Maintz D, Bunck AC (2015) Mapping tissue inhomogeneity in acute myocarditis: a novel analytical approach to quantitative myocardial edema imaging by T2-mapping. *J Cardiovasc Magn Reson* 17:115
56. Foltz WD, Al-Kwif O, Sussman MS, Stainsby JA, Wright GA (2003) Optimized Spiral Imaging for Measurement of Myocardial T2 Relaxation. *Magn Reson Med* 49:1089–1097
57. Sparrow P, Amirabadi A, Sussman MS, Paul N, Merchant N (2009) Quantitative Assessment of Myocardial T2 Relaxation Times in Cardiac Amyloidosis. *J Cardiovasc Magn Reson* 30:942–946
58. He T, Gatehouse PD, Anderson LJ, Tanner M, Keegan J, Pennell DJ, Firmin DN (2006) Development of a Novel Optimized Breathhold Technique for Myocardial T2 Measurement in Thalassemia. *J Magn Reson Imaging* 24:24:580–585 (2006)
59. Gouya H, Vignaux O, LeRoux P, Chanson P, Bertherat J, Bertagna X, Legmann P (2008) Rapidly Reversible Myocardial Edema in Patients with Acromegaly: Assessment with Ultrafast T2 Mapping in a Single-Breath-Hold MRI Sequence. *Am J Roentgenol* 190:1576-1582
60. Huang T-Y, Liu Y-J, Stemmer A, Poncelet BP (2007) T2 Measurement of the Human Myocardium Using a T2-Prepared Transient-State TrueFISP Sequence. *Magn Reson Med* 57:960–966
61. Giri S, Chung Y-C, Merchant A, Mihai G, Rajagopalan S, Raman SV, Simonetti OP (2009) T2 quantification for improved detection of myocardial edema. *J Cardiovasc Magn Reson* 11:56
62. Verhaert D, Thavendiranathan P, Giri S, Mihai G, Rajagopalan S, Simonetti OP, Raman SV (2011) Direct T2 Quantification of Myocardial Edema in Acute Ischemic Injury. *JACC Cardiovasc Imaging* 4:269–278
63. vonKnobelsdorff-Brenkenhoff F, Prothmann M, Dieringer MA, Wassmuth R, Greiser A, Schwenke C, Niendorf T, Schulz-Menger J (2013) Myocardial T1 and T2 mapping at 3 T: reference values, influencing factors and implications. *J Cardiovasc Magn Reson* 15:53:53
64. Baeßler B, Schaarschmidt F, Stehning C, Schnackenburg B, Maintza D, Bunck AC (2015) A systematic evaluation of three different cardiac T2-mapping sequences at 1.5 and 3T in healthy volunteers. *Eur J Radiol* 84:2161–2170
65. Blume U, Lockie T, Stehning C, Sinclair S, Uribe S, Razavi R, Schaeffter T (2009) Interleaved T1 and T2 Relaxation Time Mapping for Cardiac Applications. *J Magn Reson Imaging* 29:480–487
66. Sprinkart AM, Luetkens JA, Träber F, Doerner J, Gieseke J, Schnackenburg B, Schmitz G, Thomas D, Homs R (2015) Gradient Spin Echo (GraSE) imaging for fast myocardial T2 mapping. *J Cardiovasc Magn Reson* 17:12
67. Miller CA, Fildes JE, Ray SG, Doran H, Yonan N, Williams SG, Schmitt M (2013) Non-invasive approaches for the diagnosis of acute cardiac allograft rejection. *Heart* 99 (7):445-453. doi:10.1136/heartjnl-2012-302759
68. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, Dobbels F, Kirk R (2013) The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report–2013; focus theme: age. *J Heart Lung Transplant* 32:951–964. *J Heart Lung Transplant* 32:951-964

69. Marie PY, Angioi M, Carreaux JP, Escanye JM, Mattei S, Tzvetanov K, Claudon O, Hassan N, Danchin N, Karcher G, Bertrand A, Walker PM, Villemot JP (2001) Detection and Prediction of Acute Heart Transplant Rejection With the Myocardial T2 Determination Provided by a Black-Blood Magnetic Resonance Imaging Sequence. *J Am Coll Cardiol* 37:825–831
70. Usman AA, Taimen K, Wasielewski M, McDonald J, Shah S, Giri S, Cotts W, McGee E, Gordon R, Collins JD, Mark M, Carr JC (2012) Cardiac Magnetic Resonance T2 Mapping in the Monitoring and Follow-up of Acute Cardiac Transplant Rejection: A Pilot Study. *Circ Cardiovasc Imaging* 5:782–790
71. Miller CA, Naish JH, Shaw SM, Yonan N, Williams SG, Clark D, Bishop PW, Ainslie MP, Borg A, Coutts G, Parke GJM, Ray S, Schmitt M (2014) Multiparametric cardiovascular magnetic resonance surveillance of acute cardiac allograft rejection and characterisation of transplantation-associated myocardial injury: a pilot study. *J Cardiovasc Magn Reson* 16:52
72. Shanna OP, Maheshwari A, Thaker K (1993) Myocardial Sarcoidosis. *Chest* 103:253-258
73. Silverman KJ, Hutchins GM, Bulkley BH (1978) Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. *Circulation* 58:1204-1211
74. Hiraga H, Iwai K, Hiroe M, Omori F, Sekiguchi M, Tachibana T (1993) Guideline for Diagnosis of Cardiac Sarcoidosis: Study Report on Diffuse Pulmonary Diseases From the Japanese Ministry of Health and Welfare. *Japanese Ministry of Health and Welfare*:23-24
75. Patel AR, Klein MR, Chandra S, Spencer KT, DeCara JM, Lang RM, Burke MC, Garrity ER, Hogarth DK (2013) Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. *Eur J Heart Fail* 13 1231–1237
76. Smedema JP, Snoep G, vanKroonenburgh MPG, vanGeuns RJ, Dassen WRM, Gorgels APM, Crijns HJGM (2005) Evaluation of the Accuracy of Gadolinium-Enhanced Cardiovascular Magnetic Resonance in the Diagnosis of Cardiac Sarcoidosis. *J Am Coll Cardiol* 45:1683-1690
77. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB (2009) Detection of Myocardial Damage in Patients with Sarcoidosis. *Circulation* 120:1969-1977
78. Greulich S, Deluig CC, Gloekler S, Wahl A, Zürn C, Kramer U, Nothnagel D, Bültel H (2013) CMR Imaging Predicts Death and Other Adverse Events in Suspected Cardiac Sarcoidosis. *JACC Cardiovasc Imaging* 6:501–511
79. Nadel J, Lancefield T, Voskoboinik A, Taylor AJ (2015) Late gadolinium enhancement identified with cardiacmagnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. *Eur Heart J Cardiovasc Imaging* 16:634–641
80. Tadamura E, Yamamuro M, Kubo S, Kanao S, Saga T, Harada M, Ohba M, Hosokawa R, Kimura T, Kita T, Togashi K (2005) Effectiveness of Delayed Enhanced MRI for Identification of Cardiac Sarcoidosis Comparison with Radionuclide Imaging. *Am J Roentgenol* 185:110-115
81. Crouser ED, Ono C, Tran T, He X, Raman SV (2014) Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. *Am J Respir Crit Care Med* 189:109-112
82. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, Miura M, Sakaue S (2008) Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. *Eur J Nucl Med Mol Imaging* 35:933–941
83. Orii M, Hirata K, Tanimoto T, Ota S, Shiono Y, Yamano T, Matsuo Y, Ino Y, Yamaguchi T (2015) Comparison of cardiac MRI and 18F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complete heart block. *Heart Rhythm* 12:2477–2485
84. Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, Yu Z, Addetia K, Mor-Avi V (2016) Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction Risk Stratification Using Cardiovascular Magnetic Resonance. *Circ Cardiovasc Imaging* 9:e003738
85. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 25:1271-1277

86. Ballocca F, D'Ascenzo F, Moretti C, Omedè P, Cerrato E, Barbero U, Abbate A, Bertero M, Zoccai GB, Gaita F (2015) Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. *Eur J Prev Cardiol* 22:1435-1441
87. Apte M, McGwin G, Vilá LM, Kaslow RA, Alarcón GS, Reveill JD (2008) Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort (LV). *Rheumatology (Oxford)* 47:362-367
88. Abdel-Aty H, Siegle N, Natusch A, Gromnica-Ihle E, Wassmuth R, Dietz R, Schulz-Menger J (2008) Myocardial tissue characterization in systemic lupus erythematosus: value of a comprehensive cardiovascular magnetic resonance approach. *Lupus* 17:Lupus (2008) 2017, 2561–2567
89. Mavrogeni S, Bratis K, Markussis V, Spargias C, Papadopoulou E, Papamentzelopoulos S, Constadoulakis P, Matsoukas E, Kyrou L, Kolovou G (2013) The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis. *Lupus* 22:34-43
90. Singh JA, Woodard PK, Da'vila-Roman VG, Waggoner AD, Gutierrez FR, Zheng J, Eisen SA (2005) Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report. *Lupus* 14:137–144
91. Puntmann VO, D'Cruz D, Smith Z, Pastor A, Choong P, Voigt T, Carr-White G, Sangle S, Schaeffter T, Nagel E (2013) Native Myocardial T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Subclinical Cardiomyopathy in Patients With Systemic Lupus Erythematosus. *Circ Cardiovasc Imaging* 6:295-301
92. Zhang Y, Corona-Villalobos CP, Kiani AN, Eng J, Kamel IR, Zimmerman SL, Petri M (2015) Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus. *Int J Cardiovasc Imaging* 31:389–397
93. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. *Nature* 423:356-361
94. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, SJ SJJ, Gabriel SE (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum* 52:402-411
95. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, Canning C, Schneeweiss S (2006) Patterns of cardiovascular risk in rheumatoid arthritis. *Ann Rheum Dis* 65:1608-1612
96. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 52:722-732
97. Giles JT, Fernandes V, Lima JA, Bathon JM (2005) Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. *Arthritis Res Ther* 7:195-207
98. Kobayashi Y, Giles JT, Hirano M, Yokoe I, Nakajima Y, Bathon JM, Lima JAC, Kobayashi H (2010) Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study. *Arthritis Res Ther* 12:R171
99. Mavrogeni S, Bratis K, Sfendouraki E, Papadopoulou E, Kolovou G (2013) Myopericarditis, as the first sign of rheumatoid arthritis relapse, evaluated by cardiac magnetic resonance. *Inflamm Allergy Drug Targets* 12:206-211
100. Ntusi NAB, Piechnik SK, Francis JM, Ferreira VM, Matthews PM, Robson MD, Wordsworth PB, Neubauer S, Karamitsos TD (2015) Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping. *JACC Cardiovasc Imaging* 8:52 56 – 36
101. Steen VD, Medsger TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. *Arthritis Rheum* 43:2437–2444
102. Champion HC (2008) The heart is scleroderma. *Rheum Dis Clin North Am* 34:181-190
103. D'Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. *Am J Med* 46:428–440
104. Medsger TJ, Masi A (1973) Survival with Scleroderma. II. A life-table analysis of clinical and demographic factors in 258 male U.S. veteran patients. *J Chronic Dis* 26:647-660

105. Tzelepis GE, Kelekis NL, Plastiras SC, Mitseas P, Economopoulos N, Kampolis C, Gialafos EJ, Moysakis I, Moutsopoulos HM (2007) Pattern and Distribution of Myocardial Fibrosis in Systemic Sclerosis: A Delayed Enhanced Magnetic Resonance Imaging Study. *Arthritis Rheum* 56:3827-3836
106. Hachulla A-L, Launay D, Gaxotte V, Groote Pd, Lamblin N, Devos P, Hatron P-Y, Beregi J-P, Hachulla E (2009) Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. *Ann Rheum Dis* 68:1878-1884
107. Rodríguez-Reyna TS, Morelos-Guzman M, Hernández-Reyes P, Montero-Duarte K, Martínez-Reyes C, Reyes-Utrera C, Vazquez J, Morales-Blanchir J (2015) Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography. *Rheumatology (Oxford)* 54:647-654
108. Sano M, Satoh H, Suwa K, Nobuhara M, Saitoh T, Saotome M, Urushida T, Katoh H, Shimoyama K, Suzuki D, Ogawa N (2015) Characteristics and clinical relevance of late gadolinium enhancement in cardiac magnetic resonance in patients with systemic sclerosis. *Heart Vessels* 30:779-788
109. Barison A, Gargani L, Marchi DD, Aquaro GD, Guiducci S, Picano E, Cerinic MM, Pingitore A (2015) Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance. *Eur Heart J Cardiovasc Imaging* 16:74-80
110. Ntusi NAB, Piechnik SK, Francis JM, Ferreira VM, Rai ABS, Matthews PN, Robson MD, Moon J, Wordsworth PB, Neubauer S, Karamitsos TD (2014) Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis – a clinical study using myocardial T1-mapping and extracellular volume quantification. *J Cardiovasc Magn Reson* 16:21
111. Kobayashi H, Yokoe I, Hirano M, Nakamura T, Nakajima Y, Fontaine KR, Giles JT, Kobayashi Y (2009) Cardiac Magnetic Resonance Imaging with Pharmacological Stress Perfusion and Delayed Enhancement in Asymptomatic Patients with Systemic Sclerosis. *J Rheumatol* 36:106-112
112. DiCesarea E, Battistia S, DiSibioa A, Cipriani P, Giacomelli R, Liakouli V, Ruscitti P, Masciocchia C (2013) Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). *Eur J Radiol* 82:e268-273
113. Schicchi N, Valeri G, Moroncini G, Agliata G, Salvolini L, Gabrielli A, Giovagnoni A (2014) Myocardial perfusion defects in scleroderma detected by contrast-enhanced cardiovascular magnetic resonance. *Radiol Med* 119:885-894
114. Mavrogeni SI, Bratis K, Karabela G, Spiliotis G, Wijk K, Hautemann D, Reiber JH, Koutsogeorgopoulou L (2015) Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis. *Inflamm Allergy Drug Targets* 14:29-36
115. Thuny F, Lovric D, Schnell F, Bergerot C, Ernande L, Cottin V, Derumeaux G, Croisille P (2014) Quantification of myocardial extracellular volume fraction with cardiac MR imaging for early detection of left ventricle involvement in systemic sclerosis. *Radiology* 271:373-380

Table 1. T2w Imaging

Study	Field Strength	Sequence	Validation	Mycarditis (n)	Control (n)	Acute vs chronic cardiac inflammation	Control group	Test result	Sensitivity	Specificity	Diagnostic accuracy	PPV	NPV
Laiassy et al, Chest 2002 ³¹	1.5 T	T2w sequence with long TR/TE	Clinical	20	7	Acute	Healthy Participants	Qualitative	45%	100%	59%	100%	39%
Abdel-Aty et al, J Am Col Cardiol 2005 ²²	1.5 T	T2w triple inversion recovery sequence	Clinical	25	23	Acute	Healthy Participants	ER cut off 1.9	84%	74%	79%	78%	81%
Gutberlet et al, Radiology 2008 ²³	1.5 T	T2w triple inversion recovery sequence	EMB	48	35	Chronic	Other diagnoses	ER cut off 2	67%	69%	68%	74%	60%
Röttgen et al, Eur Radiol 2011 ³⁴	1.5 T	T2w triple inversion recovery sequence	EMB	82	49	Acute	No inflammation on EMB	ER cut off 2	58%	57%	58%	73%	41%
Voigt et al, Eur Radiol 2011 ³⁵	1.5 T	T2w triple inversion recovery sequence	EMB	12	11	Chronic	No inflammation on EMB	ER cut off 1.8	92%	82%	87%	85%	90%
Lurz et al, JACC Cardiovasc Imaging 2012 ^{36, 42}	1.5 T	T2w triple inversion recovery sequence	EMB	53	17	Acute	Other diagnoses	ER cut off 1.9	64%	65%	64%	85%	37%
Lurz et al, JACC Cardiovasc Imaging 2012 ^{36, 42}	1.5 T	T2w triple inversion recovery sequence	EMB	30	32	Chronic	Other diagnoses	ER cut off 1.9	42%	66%	54%	58%	50%
Chu et al, Int J Cardiovasc Im 2013 ³⁷	1.5 T	T2w triple inversion recovery sequence	Clinical	35	10	Acute	Healthy Participants	Qualitative	69%	100%	76%	100%	48%
Ferreira et al, JACC Cardiovasc Imaging 2013 ³⁸	1.5 T	Acquisition for cardiac unflied T2 oedema sequence	Clinical	50	45	Acute	Healthy Participants	ER cut off 2.2	67%	55%	61%	78%	42%
Sramko et al, Am J Cardiol 2013 ³⁹	1.5 T	T2w dark blood sequence	EMB	15	27	Chronic	Idiopathic DCM	ER cut off 1.9	13%	93%	64%	51%	66%
Ferreira et al, J Cardiovasc Magn Reson 2014 ⁴⁰	1.5 T	T2w triple inversion recovery sequence	Clinical	60	50	Acute	Healthy Participants	ER cut off 2.0	48%	86%	65%	81%	58%
Radunski et al, JACC Cardiovasc Imaging 2014 ⁴¹	1.5 T	T2w triple inversion recovery sequence	Clinical	104	21	Mostly Acute	Healthy Participants	ER cut off 2.2	76%	42%	70%	84%	30%
Luetkens et al, Radiology 2014 ⁴²	3 T	T2w triple inversion recovery sequence	Clinical	24	42	Acute	Healthy Participants	ER cut off 2.09	79%	61%	68%	58%	82%
Schwab et al, Rofo 2015 ⁴³	1.5 T	T2w triple inversion recovery sequence	Clinical	43	35	Acute	Healthy Participants	Qualitative	56%	100%	76%	100%	65%
Hinojar et al, JACC Cardiovasc Imaging 2015 ⁴⁴	1.5 T / 3 T	T2w triple inversion recovery sequence	Clinical	61	40	Acute	Healthy Participants	Qualitative / ER	56%	94%	71%	95%	55%
Luetkens et al, Eur H J Cardiovasc im 2016 ⁴⁵	1.5 T	T2w triple inversion recovery sequence	Clinical	34	50	Acute	Healthy Participants	ER cut off 1.9	50%	94%	76%	85%	73%
Pooled data				696	494				62%	76%	67%	78%	58%
Chronic inflammation only									55%	76%	65%	69%	63%
Acute inflammation only									63%	76%	68%	80%	57%
Healthy participants as control									64%	79%	70%	81%	61%
Other diagnoses as controls									58%	69%	63%	73%	54%

DCM – dilated cardiomyopathy; ER – oedema ratio; EMB – endomyocardial biopsy; NPV – negative predictive value; PPV – positive predictive value; TE – echotime; TR – repeat time; T2w – T2 weighted
a; One study examining two groups of patients with acute and chronic cardiac inflammation.

Table 2. Early gadolinium enhancement

Study	Field Strength	Sequence	Validation	Mycarditis (n)	Control (n)	Acute versus chronic cardiac inflammation	Control group	Test result	Sensitivity	Specificity	Diagnostic accuracy	PPV	NPV
Friedrich et al, Circulation 1998 ^{46, 47}	1 T	T1w spin echo sequence	Clinical	19	18	Acute	Healthy Participants	gRE	84%	89%	86%	89%	84%
Laiassy et al, Chest 2002 ^{31, 42}	1 T	T1w sequence with short TR/TE	Clinical	20	7	Acute	Healthy Participants	MSE cut off 45%	85%	100%	89%	100%	70%
Abdel-Aty et al, J Am Col Cardiol 2005 ²²	1.5 T	T1w spin echo sequence	Clinical	25	23	Acute	Healthy Participants	gRE cut off 4.0	80%	68%	75%	74%	75%
Gutberlet et al, Radiology 2008 ²³	1.5 T	T1w fast spin echo sequence	EMB	48	35	Chronic	Other diagnoses	gRE cut off 4.0	63%	86%	73%	86%	63%
Röttgen et al, Eur Radiol 2011 ³⁴	1.5 T	T1w fast spin echo sequence	EMB	82	49	Acute	No inflammation on EMB	gRE cut off 4.0	49%	74%	57%	78%	43%
Voigt et al, Eur Radiol 2011 ³⁵	1.5 T	T1w spin echo sequence	EMB	12	11	Chronic	No inflammation on EMB	gRE cut off 4.0	58%	64%	61%	64%	58%
Lurz et al, JACC Cardiovasc Imaging 2012 ^{36, 42}	1.5 T	T1w fast spin echo sequence	EMB	53	17	Acute	Other diagnoses	gRE cut off 4.0	76%	53%	70%	83%	41%
Lurz et al, JACC Cardiovasc Imaging 2012 ^{36, 42}	1.5 T	T1w fast spin echo sequence	EMB	30	32	Chronic	Other diagnoses	gRE cut off 4.0	73%	21%	48%	51%	40%
Chu et al, Int J Cardiovasc Im 2013 ³⁷	1.5 T	T1w turbo spin echo sequence	Clinical	35	10	Acute	Healthy Participants	gRE cut off 4.0	63%	90%	69%	96%	41%
Sramko et al, Am J Cardiol 2013 ³⁹	1.5 T	T1w turbo flash sequence	EMB	15	27	Chronic	Idiopathic DCM	MSE cut off 45%	40%	96%	76%	85%	74%
Radunski et al, JACC Cardiovasc Imaging 2014 ⁴¹	1.5 T	T1w spin echo sequence	Clinical	104	21	Mostly Acute	Healthy Participants	MSE cut off 56%	63%	71%	59%	91%	31%
Luetkens et al, Radiology 2014 ⁴²	3 T	T1w fast spin echo sequence	Clinical	24	42	Acute	Healthy Participants	gRE cut off 4.0	83%	42%	60%	53%	77%
Schwab et al, Rofo 2015 ⁴³	1.5 T	T1w fast spin echo sequence	Clinical	43	35	Acute	Healthy Participants	Qualitative assessment	51%	94%	71%	92%	61%
Luetkens et al, Eur H J Cardiovasc im 2016 ⁴⁵	1.5 T	T1w fast spin echo sequence	Clinical	34	50	Acute	Healthy Participants	gRE cut off 1.95	77%	62%	67%	58%	80%
Pooled data				544	377				65%	69%	67%	75%	58%
Chronic inflammation only									62%	66%	64%	65%	64%
Acute inflammation only									66%	70%	67%	78%	56%
Healthy participants as control									69%	70%	69%	77%	60%
Other diagnoses as controls									61%	67%	63%	72%	55%

DCM – dilated cardiomyopathy; EMB – endomyocardial biopsy; gRE – global relative enhancement; MSE – myocardial signal enhancement; NPV – negative predictive value; PPV – positive predictive value; TE – echo time; TR – repeat time; T1w – T1 weighted
a; One study examining two groups of patients with acute and chronic cardiac inflammation.

Table 3. Late gadolinium enhancement

Study	Field Strength	Sequence	Validation	Myocarditis (n)	Control (n)	Acute versus chronic cardiac inflammation	Control group	Sensitivity	Specificity	Diagnostic accuracy	PPV	NPV
Abdel-Aty et al, J Am Col Cardiol 2005 ²²	1.5 T	Inversion-recovery gradient echo sequence	Clinical	25	23	Acute	Healthy Participants	44%	100%	71%	78%	62%
Mahrholdt et al, Circulation 2006 ²³	1.5 T	Inversion-recovery gradient echo sequence	EMB	102	26	Acute	No inflammation on EMB	87%	96%	89%	99%	65%
Gutberlet et al, Radiology 2008 ²⁴	1.5 T	Inversion-recovery gradient echo sequence	EMB	48	35	Chronic	Other diagnoses	27%	80%	49%	65%	44%
Yilmaz et al, Heart 2008 ²⁷	1.5 T	Inversion-recovery gradient echo sequence	EMB	48	23	Acute	No inflammation on EMB	35%	83%	51%	81%	38%
Röttgen et al, Eur Radiol 2011 ²⁴	1.5 T	Inversion-recovery gradient echo sequence	EMB	82	49	Acute	No inflammation on EMB	31%	88%	52%	84%	39%
Voigt et al, Eur Radiol 2011 ²²	1.5 T	Inversion-recovery gradient echo sequence	EMB	12	11	Chronic	No inflammation on EMB	58%	45%	52%	53%	50%
Lurz et al, JACC Cardiovasc Imaging 2012 ^{28, a}	1.5 T	Inversion-recovery turbo gradient echo sequence	EMB	53	17	Acute	Other diagnoses	74%	65%	72%	87%	44%
Lurz et al, JACC Cardiovasc Imaging 2012 ^{28, a}	1.5 T	Inversion-recovery turbo gradient echo sequence	EMB	30	32	Chronic	Other diagnoses	61%	35%	48%	51%	44%
Chu et al, Int J Cardiovasc Im 2013 ²⁷	1.5 T	Inversion-recovery gradient echo sequence	Clinical	35	10	Acute	Healthy Participants	77%	60%	73%	87%	43%
Sramko et al, Am J Cardiol 2013 ²⁷	1.5 T	Phase-sensitive inversion-recovery sequence	Clinical	15	27	Chronic	Idiopathic DCM	87%	44%	59%	46%	86%
Ferreira et al, J Cardiovasc Magn Reson 2014 ²⁵	1.5 T	Phase-sensitive inversion-recovery sequence	Clinical	60	50	Acute	Healthy Participants	72%	97%	83%	98%	67%
Radunski et al, JACC Cardiovasc Imaging 2014 ²⁵	1.5 T	Phase-sensitive inversion-recovery sequence	Clinical	104	21	Mostly Acute	Healthy Participants	61%	100%	68%	100%	34%
Luetkens et al, Radiology 2014 ²²	3 T	Inversion-recovery gradient echo sequence	Clinical	24	42	Acute	Healthy Participants	75%	100%	91%	100%	88%
Schwab et al, Rofo 2015 ²²	1.5 T	Inversion-recovery turbo gradient echo sequence	Clinical	43	35	Acute	Healthy Participants	86%	100%	92%	100%	85%
Hinojar et al, JACC Cardiovasc Imaging 2015 ²²	1.5 T / 3 T	Inversion-recovery sequence	Clinical	61	40	Acute	Healthy Participants	72%	100%	83%	100%	79%
Luetkens et al, Eur H J Cardiovasc im 2016 ²²	1.5 T	Inversion-recovery gradient echo sequence	Clinical	34	50	Acute	Healthy Participants	74%	100%	89%	100%	85%
Pooled data				776	491			63%	85%	72%	87%	59%
Chronic inflammation only								49%	53%	51%	51%	51%
Acute inflammation only								65%	95%	75%	96%	59%
Healthy participants as control								70%	98%	81%	98%	69%
Other diagnoses as controls								57%	70%	62%	77%	48%

DCM – dilated cardiomyopathy; EMB – endomyocardial biopsy; NPV – negative predictive value; PPV – positive predictive value
a; One study examining two groups of patients with acute and chronic cardiac inflammation

Table 4. Lake Louise Criteria

Study	Field Strength	Validation	Myocarditis (n)	Control (n)	Acute versus chronic cardiac inflammation	Control group	CMR sequences	Sensitivity	Specificity	Diagnostic accuracy	PPV	NPV
Abdel-Aty et al, J Am Col Cardiol 2005 ^{22, 22}	1.5 T	Clinical	25	23	Acute	Healthy Participants	ER, gRE, LGE	76%	96%	86%	95%	79%
Gutberlet et al, Radiology 2008 ²⁴	1.5 T	EMB	48	35	Chronic	Other diagnoses	ER, gRE, LGE	63%	89%	74%	88%	63%
Voigt et al, Eur Radiol 2011 ²²	1.5 T	EMB	12	11	Chronic	No inflammation on EMB	ER, gRE, LGE	75%	73%	74%	75%	73%
Lurz et al, JACC Cardiovasc Imaging 2012 ^{28, a}	1.5 T	EMB	53	17	Acute	Other diagnoses	ER, gRE, LGE	81%	71%	79%	90%	55%
Lurz et al, JACC Cardiovasc Imaging 2012 ^{28, a}	1.5 T	EMB	30	32	Chronic	Other diagnoses	ER, gRE, LGE	63%	40%	51%	53%	50%
Chu et al, Int J Cardiovasc Im 2013 ²⁷	1.5 T	Clinical	35	10	Acute	Healthy Participants	Qualitative T2w assessment, gRE, LGE	77%	90%	80%	96%	53%
Radunski et al, JACC Cardiovasc Imaging 2014 ²⁵	1.5 T	Clinical	104	21	Mostly Acute	Healthy Participants	ER, MSE, LGE	84%	57%	79%	90%	41%
Luetkens et al, Radiology 2014 ²²	3 T	Clinical	24	42	Acute	Healthy Participants	ER, gRE, LGE	92%	80%	85%	79%	92%
Schwab et al, Rofo 2015 ²²	1.5 T	Clinical	43	35	Acute	Healthy Participants	Qualitative T2w assessment, qualitative EGE assessment, LGE	67%	100%	82%	100%	72%
Luetkens et al, Eur H J Cardiovasc im 2016 ²²	1.5 T	Clinical	34	50	Acute	Healthy Participants	ER, gRE, LGE	82%	98%	92%	97%	89%
Pooled data				408	276			77%	81%	79%	86%	70%
Chronic inflammation only								65%	67%	66%	69%	62%
Acute inflammation only								80%	87%	83%	91%	73%
Healthy participants as control								80%	89%	84%	91%	75%
Other diagnoses as controls								71%	67%	69%	77%	60%

DCM – dilated cardiomyopathy; ER – oedema ratio; EMB – endomyocardial biopsy; gRE – global relative enhancement; MSE – myocardial signal enhancement; NPV – negative predictive value; PPV – positive predictive value; T1w – T1 weighted; T2w – T2 weighted
a; One study examining two groups of patients with acute and chronic cardiac inflammation

Table 5. Parametric mapping

T2 mapping													
Study	Field Strength	Sequence	Validation n	Myocarditis (n)	Control (n)	Acute versus chronic cardiac inflammation	Control group	Test Result	Sensitivity	Specificity	Diagnostic accuracy	PPV	NPV
Thavendirathan et al, Circ Cardiovasc Imaging 2012 ²¹	1.5 T	T2p-SFFP	Clinical	20	30	Acute	Healthy Participants	T2 cut off 59 ms	94%	97%	96%	95%	96%
Radunski et al, JACC Cardiovasc Imaging 2014 ²²	1.5 T	T2 multiecho sequence	Clinical	87	21	Mostly Acute	Healthy Participants	T2 cut off 61 ms	57%	89%	63%	95%	35%
Bohnen et al, Circ Cardiovasc Imaging 2015 ²³	1.5 T	Hybrid gradient and spin-echo multiecho sequence	EMB	16	15	Chronic	No inflammation	T2 cut off 60 ms	94%	60%	78%	71%	90%
Baessler et al, J Cardiovasc Magn Reson 2015 ²⁴	1.5 T	GraSE	LLC	31	30	Acute	Healthy Participants	max T2 68ms/madSD 0.22	81%	83%	82%	83%	81%
Luetkens et al, Eur H J Cardiovasc Im 2016 ²⁵	1.5 T	GraSE	Clinical	34	50	Acute	Healthy Participants	T2 cut off 59.9 ms	79%	92%	87%	87%	87%
Pooled data									72%	87%	79%	88%	71%
Chronic inflammation only									94%	60%	78%	71%	90%
Acute inflammation only									70%	91%	79%	91%	70%
Healthy participants as control									70%	91%	79%	91%	70%
Other diagnoses as controls									94%	60%	78%	71%	90%
T1 mapping													
Study	Field Strength	Sequence	Validation n	Myocarditis (n)	Control (n)	Acute versus chronic cardiac inflammation	Control group	Test Result	Sensitivity	Specificity	Diagnostic accuracy	PPV	NPV
Ferreira et al, J Cardiovasc Magn Reson 2014 ²⁶	1.5 T	ShMOLLI	Clinical	60	50	Acute	Healthy Participants	T1 cut off 990 ms	90%	88%	89%	90%	88%
Luetkens et al, Radiology 2014 ²⁷	3 T	MOLLI	Clinical	24	42	Acute	Healthy Participants	T1 cut off 1140 ms	92%	91%	91%	85%	95%
Radunski et al, JACC Cardiovasc Imaging 2014 ²²	1.5 T	MOLLI	Clinical	104	21	Mostly Acute	Healthy Participants	T1 cut off 1074 ms	64%	90%	68%	97%	34%
Hinojar et al, JACC Cardiovasc Imaging 2015 ²⁸	1.5 T / 3 T	MOLLI	Clinical	61	40	Acute	Healthy Participants	T1 cut off 992 ms on 1.5T, 1098 ms on 3T	98%	100%	99%	100%	99%
Luetkens et al, Eur H J Cardiovasc im 2016 ²⁵	1.5 T	MOLLI	Clinical	34	50	Acute	Healthy Participants	T1 cut off 1000 ms	85%	96%	92%	94%	90%
Luetkens et al, Eur H J Cardiovasc im 2016 ²⁵	1.5 T	ShMOLLI	Clinical	34	50	Acute	Healthy Participants	T1 cut off 852 ms	88%	84%	86%	79%	91%
Pooled data									82%	91%	86%	92%	81%
ECV													
Study	Field Strength	T1 mapping Sequence	Validation n	Myocarditis (n)	Control (n)	Acute versus chronic cardiac inflammation	Control group	Test Result	Sensitivity	Specificity	Diagnostic accuracy	PPV	NPV
Luetkens et al, Radiology 2014 ²⁷	3 T	MOLLI	Clinical	24	42	Acute	Healthy Participants	ECV cut off 26%	67%	81%	76%	67%	81%
Radunski et al, JACC Cardiovasc Imaging 2014 ²²	1.5 T	MOLLI	Clinical	104	21	Mostly Acute	Healthy Participants	ECV cut off 29%	73%	90%	76%	97%	40%
Luetkens et al, Eur H J Cardiovasc im 2016 ²⁵	1.5 T	MOLLI	Clinical	34	50	Acute	Healthy Participants	ECV cut off 29%	70%	76%	74%	67%	79%
Luetkens et al, Eur H J Cardiovasc im 2016 ²⁵	1.5 T	ShMOLLI	Clinical	34	50	Acute	Healthy Participants	ECV cut off 30%	57%	92%	78%	83%	75%
Pooled data									69%	84%	76%	84%	69%

DCM – dilated cardiomyopathy; EMB – endomyocardial biopsy; GraSE - Gradient spin echo T2 sequence; LLC – Lake Louise Criteria; MOLLI - Modified Look-Locker inversion recovery sequence; NPV – negative predictive value; PPV – positive predictive value; ShMOLLI - Shortened modified Look-Locker inversion recovery sequence; T2p-SFFP - T2 prepared steady-state free precession sequence
 a. Two separate T1 mapping sequences employed in one study: MOLLI and ShMOLLI

Figure 1

Patient with acute viral myocarditis. 1A; Late enhancement imaging. Epicardial and mid-wall late enhancement (green arrows) in mid anterolateral and apical lateral segments. 1B; T1 mapping, MOLLI sequence. Elevated T1 values in mid-wall and epicardial portion of basal – mid anterolateral and apical lateral segments (green arrows; T1 values in anterolateral wall: 1152 ms, T1 values in basal inferoseptum: 1031 ms). 1C: T2 mapping, T2-prepared SFFP sequence. Elevated T2 values in epicardial portion of mid anterolateral and apical lateral segments (green arrows; T2 values in mid anterolateral segment: 66 ms, T2 values in basal inferoseptum: 47 ms).

